Impaired T Cell Protein Kinase C Delta Activation Decreases ERK Pathway Signaling in Idiopathic and Hydralazine-induced Lupus
Overview
Affiliations
T cells from patients with lupus or treated with the lupus-inducing drug hydralazine have defective ERK phosphorylation. The reason for the impaired signal transduction is unknown but important to elucidate, because decreased T cell ERK pathway signaling causes a lupus-like disease in animal models by decreasing DNA methyltransferase expression, leading to DNA hypomethylation and overexpression of methylation-sensitive genes with subsequent autoreactivity and autoimmunity. We therefore analyzed the PMA stimulated ERK pathway phosphorylation cascade in CD4(+) T cells from patients with lupus and in hydralazine-treated cells. The defect in these cells localized to protein kinase C (PKC)delta. Pharmacologic inhibition of PKCdelta or transfection with a dominant negative PKCdelta mutant caused demethylation of the TNFSF7 (CD70) promoter and CD70 overexpression similar to lupus and hydralazine-treated T cells. These results suggest that defective T cell PKCdelta activation may contribute to the development of idiopathic and hydralazine-induced lupus through effects on T cell DNA methylation.
DNA methylation in human diseases.
Younesian S, Mohammadi M, Younesian O, Momeny M, Ghaffari S, Bashash D Heliyon. 2024; 10(11):e32366.
PMID: 38933971 PMC: 11200359. DOI: 10.1016/j.heliyon.2024.e32366.
Somers E, Goodrich J, Wang L, Harlow S, Marder W, Hassett A J Autoimmun. 2023; 142:103137.
PMID: 38064919 PMC: 10957300. DOI: 10.1016/j.jaut.2023.103137.
Perdaens O, van Pesch V Front Neurol. 2022; 12:811518.
PMID: 35281989 PMC: 8913495. DOI: 10.3389/fneur.2021.811518.
Identification of polo-like kinase 1 as a therapeutic target in murine lupus.
Li Y, Wang H, Zhang Z, Tang C, Zhou X, Mohan C Clin Transl Immunology. 2022; 11(1):e1362.
PMID: 35024139 PMC: 8733964. DOI: 10.1002/cti2.1362.
Immune Memory in Aging: a Wide Perspective Covering Microbiota, Brain, Metabolism, and Epigenetics.
Bulut O, Kilic G, Dominguez-Andres J Clin Rev Allergy Immunol. 2021; 63(3):499-529.
PMID: 34910283 PMC: 8671603. DOI: 10.1007/s12016-021-08905-x.